Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Hamilton CapTel® and Partner TV Ears to Display Telephone Communication Technology Designed for Individuals with Hearing Loss at Consumer Electronics Show

January 5, 2011 3:35 am | by Bio-Medicine.Org | News | Comments

AURORA, Neb., Jan. 5, 2011 /- Consumer Electronics Show Las Vegas Convention Center Booth #2910. For the first time, Hamilton CapTel ® will demonstrate the CapTel 800i® captioned telephone for more than 100,000 attendees at the Consumer Electronics Show (CES) in Las Vegas...

TOPICS:

Water Street Healthcare Partners Acquires OraPharma, Inc.

January 5, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

CHICAGO, Jan. 5, 2011 /- Water Street Healthcare Partners announced today that it has acquired OraPharma, Inc. from Johnson & Johnson.  Water Street, a strategic private equity firm focused exclusively on health care, plans to build OraPharma into a leading specialty...

TOPICS:

DJO Incorporated Acquires Manufacturer of Compression Therapy Products, Elastic Therapy, Inc.

January 5, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Jan. 5, 2011 /- DJO Incorporated ("DJO" or the "Company"), a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the acquisition of Elastic Therapy, Inc. (ETI). The acquisition closed yesterday, January 4,...

TOPICS:
Advertisement

New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion

January 5, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

RIDGEFIELD, Conn., Jan. 5, 2011 /- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in...

TOPICS:

InterMune to Present at J.P. Morgan Healthcare Conference

January 5, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

BRISBANE, Calif., Jan. 5, 2011 /- InterMune, Inc. (Nasdaq: ITMN ) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2011, at 4:30 p.m. EST / 1:30...

TOPICS:

Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued

January 5, 2011 2:35 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Jan. 5, 2011 /- Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients...

TOPICS:

Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12

January 5, 2011 2:35 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Jan. 5, 2011 /- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that the company will make a presentation at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 12, 2011 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time.  Bruce...

TOPICS:

ImmunGene Announces Multi-Target R & D Collaboration With Cephalon Australia for Interferon Payload Technology

January 5, 2011 12:35 am | by Bio-Medicine.Org | News | Comments

THOUSAND OAKS, Calif., Jan. 5, 2011 /- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's...

TOPICS:
Advertisement

Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection

January 4, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ -- Dongsheng Pharmaceutical International Co., Ltd. (the "Company") (OTC Bulletin Board: DNGH ) announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry...

TOPICS:

<i>How I See It: </i>Uncertainty in medical device industry

January 4, 2011 7:38 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

A recent development – the FDA's intention to rescind a 510(k) medical device registration held by ReGen Biologics Inc. – signals the FDA intends to broaden its regulatory powers, leaving companies in the medical device industry and those that invest in development of medical technologies...

TOPICS:

MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference

January 4, 2011 1:36 pm | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Jan. 4, 2011 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that the company will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 8:00 a.m. PT in San Francisco. A live webcast of the presentation will be...

TOPICS:

AngioDynamics fiscal 2Q profit edges higher

January 4, 2011 12:45 pm | by The Associated Press | News | Comments

Medical device maker AngioDynamics Inc. said Tuesday its profit edged higher in the fiscal second quarter despite a decline in revenue.AngioDynamics said its profit rose 5 percent to $3.3 million in the quarter ended Nov. 30, up from $3.1 million a year ago. On a per-share basis, its profit was...

Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article(2)

January 4, 2011 12:35 pm | by Boston Scientific | News | Comments

NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was pub

TOPICS:

Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article

January 4, 2011 12:34 pm | News | Comments

NATICK, Mass., Jan. 4, 2011 / PRNewswire / -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was pub

Perspectives on Time to Market—Part 2

January 4, 2011 11:52 am | Peridot Corp. Precision Manufacturing | Articles | Comments

For your area of the industry, what is your best recommendation for getting a medical device to market faster?

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading